Key result
Sirolimus-eluting stents achieved zero restenosis in first-in-man results, and paclitaxel-eluting stents subsequently demonstrated the capability to decrease restenosis.
The introduction of sirolimus- and paclitaxel-eluting stents represented a major breakthrough in interventional cardiology by effectively preventing restenosis.
Answers are grounded in this paper and cite their sources.
Early DES enthusiasm warrants cost scrutiny before broad adoption; leaves open questions on real-world value in routine PCI.
The publication in January 2001 of the first-in-man results showing zero restenosis after sirolimus-eluting stent implantation produced enormous excitement in the cardiological community. The long-awaited tool—a safe, restenosis-proof, easy-to-use stent— had been found. It was not too long thereafter that paclitaxel-eluting stents also demonstrated their capability to decrease restenosis.
No takes yet. Share an insight, caveat, or question.
Lemos et al. (2003) studied this question. Sirolimus-eluting stents achieved zero restenosis in first-in-man results, and paclitaxel-eluting stents subsequently demonstrated the capability to decrease restenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: